Group 1 - The core viewpoint of the article highlights the recent completion of nearly 100 million RMB in B+ round financing by Koser Medical Technology (Suzhou) Co., Ltd., aimed at product development, global market promotion, and capacity expansion [1] - Koser Medical, established in 2013, operates as a platform enterprise in the vascular interventional device sector, employing a "one core, three wings" strategy to cover various treatment areas [2] - The company has developed a comprehensive treatment system for peripheral intervention and has subsidiaries focusing on cardiac electrophysiology, coronary intervention products, and core medical material technologies [2] Group 2 - Koser Medical has invested over 300 million RMB in R&D, building a robust technology platform with hundreds of domestic and international patents, including nearly 100 PCT patents [5] - The company has successfully commercialized innovative products, including the first registered umbrella-shaped long-term filter in China and balloon products that have received multiple international certifications [5] - Koser Medical's products are utilized in approximately 2000 hospitals in China and have been registered in over 20 countries internationally [5] Group 3 - The financing history of Koser Medical includes several rounds, with significant investments from various venture capital firms, culminating in the recent B+ round led by Tietou Jushi [4][5] - The company has seen a progressive increase in funding, starting from several million RMB in Pre-A round financing in early 2017 to nearly 100 million RMB in the latest B+ round [4][5]

Core Insights - Koser Medical Technology (Suzhou) Co., Ltd. has completed nearly 100 million yuan in B+ round financing, led by Tietou Jushi, with funds allocated for core product development, global market promotion, and capacity expansion [1] Company Overview - Koser Medical was established in November 2013 and is a platform company with comprehensive production and R&D capabilities in vascular interventional devices, aiming to provide systematic solutions for clinical applications [1] - The company has successfully commercialized its innovative product, the inferior vena cava filter, which is the first umbrella-shaped long-term filter approved for registration in China, with several other innovative products set to enter clinical trials [1] - Koser Medical's balloon products in the coronary field have received registration certificates from multiple countries, including China (NMPA), the USA (FDA), the EU (CE), Japan (PMDA), and South Korea (KFDA), and have entered mainstream international markets [1] Leadership - The Chairman, General Manager, and CEO, Hu Qing, is a member of the second Life Science Instrument Professional Committee of the Chinese Society of Biomedical Engineering and has received multiple honors. He has extensive experience in management roles at Fortune 500 companies and has been in the medical device industry since 2002 [1] Financing History - The company has completed four rounds of financing prior to the recent B+ round, with investors including Dacheng Caizhi and Jushi Chuangtou [2] Business Structure - Koser Medical has formed a "one core, three wings" business layout, with the parent company focusing on a one-stop treatment system for peripheral intervention, while subsidiaries specialize in cardiac electrophysiology, coronary intervention product development, and breakthrough core medical materials technology [3] Global Strategy - The company actively practices a "Local Base, Global Reach" strategy, having acquired Ireland's Micell in 2021 to gain access to extensive clinical data and special coating technology, marking a significant step towards globalization [3] - Koser Medical has completed product registrations in over 20 countries and plans to establish more overseas subsidiaries and offices, with global sales set to officially launch in 2024 and aims for large-scale international expansion by 2026 [3]